A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block CTLA-4, PD-1, or PD-L1 and induce the activation of the immune system against cancer. Despite the efficacy of ICIs, which has improved the oncotherapy for patients with a variety of malignancies, several immune-related adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio-Infante, Nestor, Ramírez-Flores, Yoel Adbel, Castillo, Elena Cristina, Lozano, Omar, García-Rivas, Gerardo, Torre-Amione, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006991/
https://www.ncbi.nlm.nih.gov/pubmed/35433707
http://dx.doi.org/10.3389/fcell.2022.851032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006991/
https://www.ncbi.nlm.nih.gov/pubmed/35433707
http://dx.doi.org/10.3389/fcell.2022.851032

Ejemplares similares